Suppr超能文献

基于 S/MAR 的内含子与囊性纤维化跨膜电导调节因子基因的组装和功能分析。

Assembly and Functional Analysis of an S/MAR Based Episome with the Cystic Fibrosis Transmembrane Conductance Regulator Gene.

机构信息

Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, 00185 Rome, Italy.

Laboratory of Experimental and Regenerative Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.

出版信息

Int J Mol Sci. 2018 Apr 17;19(4):1220. doi: 10.3390/ijms19041220.

Abstract

Improving the efficacy of gene therapy vectors is still an important goal toward the development of safe and efficient gene therapy treatments. S/MAR (scaffold/matrix attached region)-based vectors are maintained extra-chromosomally in numerous cell types, which is similar to viral-based vectors. Additionally, when established as an episome, they show a very high mitotic stability. In the present study we tested the idea that addition of an S/MAR element to a CFTR (cystic fibrosis transmembrane conductance regulator) expression vector, may allow the establishment of a CFTR episome in bronchial epithelial cells. Starting from the observation that the S/MAR vector pEPI-EGFP (enhanced green fluorescence protein) is maintained as an episome in human bronchial epithelial cells, we assembled the CFTR vector pBQ-S/MAR. This vector, transfected in bronchial epithelial cells with mutated , supported long term wt expression and activity, which in turn positively impacted on the assembly of tight junctions in polarized epithelial cells. Additionally, the recovery of intact pBQ-S/MAR, but not the parental vector lacking the S/MAR element, from transfected cells after extensive proliferation, strongly suggested that pBQ-S/MAR was established as an episome. These results add a new element, the S/MAR, that can be considered to improve the persistence and safety of gene therapy vectors for cystic fibrosis pulmonary disease.

摘要

提高基因治疗载体的疗效仍然是开发安全有效的基因治疗方法的一个重要目标。基于 S/MAR(支架/基质附着区)的载体在许多细胞类型中以染色体外的方式维持,这类似于基于病毒的载体。此外,当作为附加体建立时,它们表现出非常高的有丝分裂稳定性。在本研究中,我们检验了这样一种想法,即在 CFTR(囊性纤维化跨膜电导调节剂)表达载体中添加 S/MAR 元件,可能允许在支气管上皮细胞中建立 CFTR 附加体。从观察到 S/MAR 载体 pEPI-EGFP(增强型绿色荧光蛋白)以附加体的形式在人支气管上皮细胞中维持的结果出发,我们组装了 CFTR 载体 pBQ-S/MAR。该载体在突变的 转染支气管上皮细胞后,支持长期 wt 的表达和活性,这反过来又对极化上皮细胞中紧密连接的组装产生了积极影响。此外,从大量增殖后的转染细胞中回收完整的 pBQ-S/MAR,但不能回收缺乏 S/MAR 元件的亲本载体,强烈表明 pBQ-S/MAR 已作为附加体建立。这些结果增加了一个新的元素,即 S/MAR,可以被认为是提高囊性纤维化肺病基因治疗载体的持久性和安全性的一个因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d08/5979583/f0eb8dcbfb7f/ijms-19-01220-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验